Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome

Program aims to be first disease-modifying treatment for this serious neurogenetic disorder

RARE : 58.85 (+0.34%)
Ultragenyx to Present at Wedbush PacGrow Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg,...

RARE : 58.85 (+0.34%)
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

FOLD : 10.34 (-0.29%)
BGNE : 146.64 (+2.00%)
RARE : 58.85 (+0.34%)
UMRX : 1.96 (-2.00%)
Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates

2Q19 Galafold (migalastat) Revenue of $44.1M Represents Highest Quarterly

FOLD : 10.34 (-0.29%)
RARE : 58.85 (+0.34%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2

Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.

BAYRY : 18.4200 (+2.62%)
RARE : 58.85 (+0.34%)
ALNY : 81.16 (+0.58%)
ARCT : 10.50 (-0.57%)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.94% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RARE : 58.85 (+0.34%)
Ultragenyx: 2Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $99.2 million in its second quarter.

RARE : 58.85 (+0.34%)
Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update

Strong Crysvita(R) (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States

RARE : 58.85 (+0.34%)
Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that it has submitted to...

RARE : 58.85 (+0.34%)
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 58.85 (+0.34%)
Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host...

RARE : 58.85 (+0.34%)
Watch for Ultragenyx Pharm to Potentially Pullback After Gaining 1.10% Yesterday

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $62.19 to a high of $63.25. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

RARE : 58.85 (+0.34%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Karyopharm Thera (KPTI , ALKS , RARE , ALNY , MNTA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

RARE : 58.85 (+0.34%)
KPTI : 9.48 (+4.52%)
ALKS : 22.04 (+1.80%)
Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it has further strengthened and diversified its Board...

EOLS : 14.43 (+2.70%)
RARE : 58.85 (+0.34%)
NUVA : 64.23 (+0.80%)
RMD : 135.56 (+0.83%)
ARCT : 10.50 (-0.57%)
SmarTrend Watching for Potential Rebound in Shares of Ultragenyx Pharm After 3.51% Loss

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $60.40 to a high of $62.49. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of...

RARE : 58.85 (+0.34%)
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

RARE : 58.85 (+0.34%)
JNJ : 132.37 (+0.77%)
ARCT : 10.50 (-0.57%)
TAK : 16.77 (+0.30%)
SmarTrend Watching for Potential Rebound in Shares of Ultragenyx Pharm After 3.40% Loss

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $60.47 to a high of $61.88. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

RARE : 58.85 (+0.34%)
Ultragenyx (RARE) Down 5.7% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 58.85 (+0.34%)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp,...

RARE : 58.85 (+0.34%)
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -5.20% and -5.68%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

RARE : 58.85 (+0.34%)

Van Meerten Stock Picks

AMD - Volume Leader
The Volume Leader today is the semiconductor company Advanced Micro Devices (AMD).
AMD +0.41
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar